Bristol-Myers Squibb Pulls Tequin Antibiotic Off the Market

PRINCETON, N.J. - Bristol-Myers Squibb Co. recently pulled its Tequin antibiotic off the market, less than three months after the company updated the drug's label to include reports of serious cases of hypoglycemia and hyperglycemia.

Eric Miller, a BMS spokesman, said the company notified health authorities on April 27 of its decision to remove Tequin (gatifloxacin) from the market. Miller said the decision to withdraw Tequin was based on its evaluated commercial potential and the company's decision to transition its pharmaceutical strategy to a specialty-driven focus.

Miller indicated that Tequin's withdrawal was not based on the drug's recently strengthened …